HydraD
Dry Eye Disease
Pre-ClinicalActive
Key Facts
About EyeD Pharma
EyeD Pharma is a private, clinical-stage biotech based in Liège, Belgium, focusing on novel drug delivery for ophthalmology. Its core technology platform involves sustained-release polymeric micro-implants designed to enhance patient compliance and reduce side effects associated with traditional eye drop regimens. The pipeline includes programs for glaucoma (TimoD in Phase I), dry eye disease (HydraD in pre-clinical), and back-of-the-eye inflammation (InflammaD in feasibility), targeting large, growing patient populations. With over 100 employees and an internal CDMO, the company pursues a fully integrated development and manufacturing strategy.
View full company profileTherapeutic Areas
Other Dry Eye Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Elate Ocular® | Cambium Bio | Phase 3 |
| OT-301 | Ocumension Therapeutics | Phase 2 |
| Avarept® Ophthalmic suspension 0.3% | Senju Pharmaceutical | Approved |
| Dry Eye Care Portfolio | YD Bio | Commercial |
| Dry Eye Studies | Oculus Research | Not Applicable (Service Provider) |
| MediPrint Lens (Dry Eye) | MediPrint Ophthalmics | Pre-clinical/Research |
| Tivanisiran | Sylentis | Phase 2/3 |
| A197 | Aramis Biosciences | Phase 2 |
| KM102 | Theratome Bio | Pre-clinical |
| iTEAR®100 Commercialization | Olympic Ophthalmics | Commercial |
| ST-100 (Vezocolmitide) | Stuart Therapeutics | Phase 3 |
| BRM421 | BRIM Biotechnology | Phase 3 |